https://www.jnj.com/media-center/press-releases/fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-the-only-egfr-targeted-therapy-that-can-be-administered-once-a-month
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest...
fdahyaluronidase
https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-breakthrough-therapy-designation-for-patients-with-advanced-head-and-neck-cancer
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™...
hyaluronidasereceivesfda
https://www.darzalex.com/
DARZALEX® & DARZALEX FASPRO® is a multiple myeloma treatment for newly diagnosed and previously treated patients. See Full Prescribing & Safety Information.
officialpatientwebsitehyaluronidase
https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of care
hyaluronidaseplusimmunotherapyshowsstrong
https://www.rybrevanthcp.com/
The official healthcare provider website for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and RYBREVANT® (amivantamab-vmjw), treatments for EGFR+...
treatmenthyaluronidasehcp
https://www.jnjmedicalconnect.com/products/rybrevant-faspro
Feb 4, 2026 - This site provides access to current scientific information about RYBREVANT FASPRO™ (amivantamab and hyaluronidase)
hyaluronidase